
Professor Amit Nathwani
Professor Amit Nathwani is the founder of NovalGen and serves as the Company’s CEO and is a member of the Board of Directors.
Professor Nathwani is a renowned serial innovator and entrepreneur. He has an international reputation for his work in cancer research, immunology, and gene therapy and has been the recipient of a number of awards, including Outstanding Achievement Award in 2016 from ESGCT and American Society of Hematology and the Ham-Wasserman Lecture award in 2019. He is well known for his dedication to translational medicine and his commonly cited pioneering work in gene therapy where he was the first to show successful correction of bleeding diathesis in patients with severe hemophilia B.
He is the Founder and was the CSO (until end 2020) and now serves as a Board member of Freeline. Over the last 20 years Professor Nathwani has coordinated numerous Phase II and III trials in the treatment of refractory chronic lymphocytic leukaemia and is an author of more than 200 publications. He is the Principal Investigator on several early phase studies and an author of several patents. He continues to serve as the Director of the Katharine Dormandy Hemophilia Centre at the Royal Free Hospital and as a Senior NIHR Investigator. Additionally, he has also been a Professor of Hematology at University College London since November 2011. Professor Nathwani graduated with MBChB from the University of Aberdeen in 1984 and is a fellow of the Royal College of Physician as well as the Royal College of Pathologist since June 1995. He holds a PhD in Molecular Biology.